Canterbury DHB
|
|
|
The following chemotherapy charts are given here and the supportive care recommended for each protocol is also given. See also Drug Usage and Prescribing in Haematology, Cytotoxic Drugs.
For drug trial charts, see the Clinical Trials page on the Intranet.
If an authorised template for the regimen is not available, the individualised template may be used to create the required regimen. DO NOT alter authorised templates.
|
Prescription Chart |
Individualised template |
|
Prescription Chart |
Atgam Equine |
UKALL 14 |
Prescription Chart |
Induction 1 |
|
Induction 2 |
|
Intensification |
|
Consolidation 1 |
|
Consolidation 2 |
|
Consolidation 3 |
|
Consolidation 4 |
|
Maintenance |
|
Other Treatments for ALL |
|
Hyper-CVAD part A |
|
Hyper-CVAD part B - methotrexate + cytarabine |
|
Modified OPAL |
|
Vincristine single dose |
See the Intrathecal Chemotherapy Medication Chart.
|
Prescription Chart |
Oral Prescriptions |
Irradiated Blood |
Patient Information Leaflet |
Rituximab + Bendamustine Cycle 1 |
|
|
||
Rituximab + Bendamustine Cycles 2 onwards |
|
|
||
FCR IV Cycle 1 |
|
|
||
FCR PO Cycle 1 |
|
|
||
FCR IV Cycle 2 onwards |
|
|
||
FCR PO Cycle 2 onwards |
|
|
||
Rituximab 375 |
|
|
|
|
Rituximab + Venetoclax Cycle 1 |
|
|
||
Rituximab + Venetoclax Cycle 2 onwards |
|
|
||
Venetoclax monotherapy Cycle 1 |
|
|
|
|
Venetoclax monotherapy Cycle 2 onwards |
|
|
|
|
Obinutuzumab + chlorambucil Cycle 1 |
|
|
||
Obinutuzumab + chlorambucil Cycle 2 onwards |
|
|
|
Prescription Chart |
Irradiated Blood |
Cladribine - IV |
||
Cladribine - subcut |
||
Pentostatin |
AML19 Trial |
Prescription Chart |
Irradiated Blood |
D(60)A 3+10 Course 1 |
|
|
D(50)A 3+8 Course 2 |
|
|
D(60)A 3+10 Course 1 with gemtuzumab x 1 dose |
|
|
FLAG-Ida Course 1 with gemtuzumab x 1 dose |
|
|
FLAG-Ida Course 1 |
|
|
FLAG-Ida Course 2 |
|
|
High dose cytarabine |
|
|
AML 19 trial – APML patients |
Prescription Chart |
Irradiated Blood |
AIDA induction |
|
|
AIDA consolidation 1 |
|
|
AIDA consolidation 2 |
|
|
AIDA consolidation 3 |
|
|
Other Treatments for AML |
Prescription Chart |
Irradiated Blood |
Low-dose cytarabine |
|
|
Low-dose cytarabine + venetoclax cycle 1 |
|
|
Low-dose cytarabine + venetoclax cycle 2 onwards |
|
|
Azacitidine + venetoclax cycle 1 |
|
|
Azacitidine + venetoclax cycle 2 onwards |
|
|
Non-trial treatments for APML |
Prescription Chart |
Irradiated Blood |
Induction Tretinoin with Arsenic Trioxide |
|
|
Consolidation - Tretinoin with Arsenic Trioxide |
|
|
Prescription Chart |
Intrathecal Chemotherapy |
|
Prescription Chart |
Azacitidine |
|
Prescription Chart |
Pamidronate Chart |
Zoledronic Acid Chart |
Oral Prescriptions |
Patient Information Leaflet |
CyBorD |
|||||
Consolidation VTD post Auto SCT |
|
||||
Consolidation VRD post Auto SCT |
|||||
VMP weekly - modified VISTA |
|
||||
Bortezomib alone |
|
||||
Elotuzumab ALLG-MM20 |
|
|
|
|
|
Prescription Chart |
Irradiated Blood |
Oral Prescriptions |
Patient Information Leaflet |
R-CVP |
|
|||
R-CHOP |
|
|||
R-CHOEP |
|
|||
Rituximab + Bendamustine |
||||
Obinutuzumab + Bendamustine cycle 1 |
|
|
|
|
Obinutuzumab + Bendamustine cycle 2 + |
|
|
|
|
Mini R-CHOP |
|
|
||
Inpatient DA-R EPOCH |
|
|
|
|
Outpatient DA-R-EPOCH Cycle 1 |
|
|
|
|
Outpatient DA-R-EPOCH Cycle 2 + |
|
|
|
|
CNS Prophylaxis – High Dose Methotrexate |
|
|
|
|
R-CEOP |
|
|||
Maintenance Rituximab |
|
|
|
|
Maintenance Obinutuzumab |
|
|
|
|
Rituximab 375 |
|
|
|
|
Mantle Cell Lymphoma |
||||
Nordic protocol – R Maxi-CHOP |
|
|
|
|
Nordic protocol – R High Dose Cytarabine |
|
|
|
|
Mantle Cell R-BAC |
|
|||
Relapsed/Refractory Lymphoma |
||||
R-ICE |
|
|
|
|
R-GDP |
|
|||
Vinorelbine and gemcitabine |
|
|
||
Burkitt-type Lymphoma |
||||
R CODOX-M - patients all ages |
|
|
|
|
R IVAC - patients 65 years or less |
|
|
|
|
R IVAC - patients over 65 |
|
|
|
|
R-Hyper CVAD |
|
|
|
|
R-Methotrexate Cytarabine |
|
|
|
|
CNS Lymphoma |
||||
MARIETTA protocol part 1 – MATRix |
|
|
|
|
MARIETTA protocol part 2 – R-ICE |
|
|
|
|
Primary CNS Lymphoma – MATRix |
|
|
|
|
Waldenstrom macroglobulinaemia/Lymphoplasmacytic lymphoma |
||||
Dexamethasone, rituximab and cyclophosphamide (DRC) |
|
|
|
|
WM Rituximab Fludarabine PO |
|
|
|
|
Rituximab + Bendamustine |
|
|
|
|
Rituximab 375 |
|
|
|
|
* There are currently no prescription sheets for these protocols. If they are required, please page the Haematology Pharmacist on 8209.
|
Prescription Chart |
Rituximab weekly 100 |
|
Rituximab weekly 375 |
|
Rituximab 375 |
|
Prescription Chart |
Multiple Myeloma: |
|
Bortezomib, thalidomide, dexamethasone |
|
Cyclophosphamide, bortezomib, dexamethasone |
|
Cyclophosphamide, thalidomide, dexamethasone |
|
Lenalidomide, dexamethasone |
|
Melphalan, prednisone, thalidomide |
|
Melphalan, prednisone |
|
Chronic Lymphocytic Leukaemia: |
|
Rituximab, fludarabine, cyclophosphamide |
|
Non-Hodgkins Lymphoma: |
|
Rituximab, cyclophosphamide, vincristine, prednisone |
|
Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone |
|
Prescription Chart |
NZBS approval form |
Pamidronate |
|
|
Pentamidine |
|
|
Privigen |
|
|
Intragam-P |
||
Evogram |
||
Ganciclovir - post-SCT |
|
|
Zoledronic Acid |
|
|
Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document.
|
|
Topic Code: 10276
Disclaimer